Myovant Sciences Ltd (MYOV) Coverage Initiated at Cowen and Company
Analysts at Cowen and Company began coverage on shares of Myovant Sciences Ltd (NASDAQ:MYOV) in a research note issued on Monday. The brokerage set an “outperform” rating on the stock.
MYOV has been the topic of several other research reports. Citigroup Inc. started coverage on Myovant Sciences in a report on Monday. They set a “buy” rating on the stock. Barclays PLC started coverage on Myovant Sciences in a report on Monday. They set an “overweight” rating and a $18.00 price objective on the stock. Robert W. Baird started coverage on Myovant Sciences in a report on Monday. They set an “outperform” rating and a $20.00 price objective on the stock. Finally, JMP Securities started coverage on Myovant Sciences in a report on Monday. They set an “outperform” rating and a $23.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $20.33.
Myovant Sciences (NASDAQ:MYOV) opened at 11.03 on Monday. The firm has a 50-day moving average price of $11.40 and a 200-day moving average price of $11.40. Myovant Sciences has a 1-year low of $10.26 and a 1-year high of $13.31. The firm’s market capitalization is $480.80 million.
ILLEGAL ACTIVITY WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2016/11/23/myovant-sciences-ltd-myov-coverage-initiated-at-cowen-and-company.html.
Myovant Sciences Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Stock Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related stocks with our FREE daily email newsletter.